SS-31 convinced the FDA to approve a mitochondrial drug for the first time. The disease it treats affects 150 Americans. The science behind it matters to everyone studying aging.

Every cell in your body runs on mitochondria. These are tiny power plants—thousands per cell—that turn food into the chemical energy your muscles, brain, and heart need. When those power plants break down, the consequences cascade: weaker muscles, a failing heart, dimming vision. For patients with Barth syndrome, a genetic mutation cripples the very molecule that holds the power plant together. SS-31, now marketed as FORZINITY, is the first drug ever approved to target that machinery directly.

The FDA granted accelerated approval in September 2025. It was a milestone for mitochondrial medicine, a field that had been chasing druggable targets inside the mitochondria for decades without landing one. Elamipretide is a four-amino-acid synthetic peptide that binds cardiolipin, a fat molecule found only on the inner mitochondrial membrane. By stabilizing cardiolipin, SS-31 keeps the energy-producing chain running. It also reduces the oxidative damage that builds up when mitochondria malfunction.

But here is where the story gets complicated—and where Peptidings earns its keep. The drug was approved for Barth syndrome, a condition affecting roughly 150 people in the United States. Three larger trials all missed their primary endpoints. Those trials covered muscle disease (218 patients), heart failure (71 patients), and vision loss (176 patients). In each case, secondary data hinted at real biological activity. But hints were not enough to satisfy the FDA's standard for those broader uses. Meanwhile, the longevity community has been injecting gray-market SS-31 for years, hoping the benefits extend to aging. This article separates the genuine achievement from the speculation.

What follows is a complete evidence review. We cover the mechanism, which is elegant. The clinical data, which is mixed. The safety profile, which is clean. And the honest gap between what we know and what we hope.

Quick Facts: SS-31 (Elamipretide) at a Glance

What Is SS-31 (Elamipretide)?

Pronunciation: ess-ess-thirty-one / eh-LAM-ih-PREH-tide (also known as Elamipretide, Bendavia, MTP-131, FORZINITY)

Your mitochondria are not just "the powerhouse of the cell"—they are the most failure-prone component of aging biology. Every mitochondrion contains its own inner membrane, folded into elaborate ridges called cristae, where the electron transport chain converts oxygen and nutrients into ATP. That membrane depends on a phospholipid called cardiolipin to hold the machinery in place. When cardiolipin degrades—through oxidation, genetic defects, or the slow accumulation of damage that comes with age—the power plants start misfiring. Electrons leak. Reactive oxygen species build up. ATP production drops. The cell struggles, and eventually, so does the tissue.

SS-31 is a four-amino-acid synthetic peptide designed to go inside the mitochondria and bind directly to cardiolipin. Its formal name is elamipretide; its brand name is FORZINITY. It was invented by Dr. Hazel Szeto at Weill Cornell Medicine, and the "SS" stands for Szeto-Schiller, the two researchers who developed the original mitochondria-targeting peptide series. The compound's amino acid sequence—D-Arg-Dmt-Lys-Phe-NH2—includes two non-natural components: a D-form arginine (mirror image of the natural L-form, which resists enzymatic breakdown) and 2',6'-dimethyltyrosine (Dmt), a modified aromatic amino acid that helps the peptide cross cell membranes despite carrying a positive charge.

What makes SS-31 unusual among peptides is that it doesn't bind a receptor on the cell surface. It penetrates cells directly—the positive charges on its arginine and lysine are shielded by the electron clouds of its aromatic rings (Dmt and phenylalanine), allowing it to pass through membranes the way a neutral molecule would. Once inside, it accumulates in the mitochondria within minutes, driven by electrostatic attraction to the negatively charged cardiolipin on the inner membrane.

Origins and Discovery

The story of SS-31 begins in the early 2000s at Weill Cornell Medical College, where Dr. Hazel Szeto was studying how to deliver antioxidants directly to mitochondria. The problem she was trying to solve was fundamental: mitochondrial oxidative stress drives damage in dozens of diseases, but conventional antioxidants (vitamin C, vitamin E, CoQ10) distribute throughout the cell and never reach the inner mitochondrial membrane in meaningful concentrations. Szeto and her colleague Peter Bhatt Schiller developed a series of small peptides—the "SS" peptides—designed with alternating aromatic and basic amino acid residues that would naturally concentrate in mitochondria.

SS-31 was the star of the series. It was the most potent at reducing mitochondrial ROS and the most effective at cell penetration. In 2006, Szeto founded Stealth BioTherapeutics to develop it as a drug. The company initially called the compound Bendavia, then MTP-131, before the generic name elamipretide was assigned.

The road to approval was not smooth. Stealth went public on Nasdaq (ticker: MITO) in February 2019, raising roughly $78 million. But the clinical failures started piling up: MMPOWER-3 for mitochondrial myopathy missed its primary endpoints in 2023. PROGRESS-HF for heart failure missed its primary endpoints in 2020. ReCLAIM-2 for macular degeneration missed its primary endpoints in 2024. Each trial showed tantalizing secondary signals—subgroup improvements, biomarker changes, secondary endpoint trends—but the headline results were negative. Stealth was taken private in November 2022 when a consortium led by Morningside Venture acquired the company.

The Barth syndrome program, based on the small but long-running TAZPOWER trial, became the lifeline. On September 19, 2025, the FDA granted accelerated approval for FORZINITY—making elamipretide the first mitochondrial-targeted therapy ever to receive FDA approval for any indication.

Mechanism of Action

Cardiolipin Binding and Cristae Stabilization

SS-31 binds directly to cardiolipin through electrostatic interactions: the positively charged D-arginine and lysine residues are attracted to the negatively charged phosphate head groups of cardiolipin. The binding occurs on the inner mitochondrial membrane, specifically at the cristae—the infolded ridges where the electron transport chain complexes are concentrated.

Cardiolipin plays a structural role that is not widely appreciated: it does not merely sit in the membrane. It actively organizes the respiratory chain complexes into "supercomplexes"—assemblies of Complexes I, III, and IV that pass electrons more efficiently when physically adjacent. When cardiolipin is damaged (by peroxidation) or defective (as in Barth syndrome), these supercomplexes dissociate, electron transfer becomes less efficient, and electrons "leak" to oxygen, generating superoxide radicals.

SS-31 stabilizes cardiolipin in a way that preserves these supercomplex interactions. It also prevents cardiolipin from converting cytochrome c into a peroxidase enzyme—a transformation that normally amplifies oxidative damage in a destructive feedback loop.

Electron Transport Chain Effects

The downstream consequences of cardiolipin stabilization are measurable:

• Complex I efficiency improves (reduced electron leakage at the NADH dehydrogenase step)
• Complex III superoxide generation decreases (the Q cycle runs more cleanly)
• Complex IV (cytochrome c oxidase) subunit assembly is maintained
• Complex V (ATP synthase) coupling improves, increasing ATP output per oxygen consumed
• Adenine nucleotide translocator (ANT) sensitivity to ADP increases, meaning mitochondria respond more quickly to energy demands

A 2020 study in PNAS (PMID 32554501) used chemical cross-linking and mass spectrometry to map SS-31's binding partners inside the mitochondria. The results confirmed interactions with ATP synthase components, cytochrome c oxidase subunits, and proteins involved in calcium handling—consistent with a compound that works at the level of the membrane itself, not at any single enzyme.

ROS Reduction

By preventing cardiolipin peroxidation and maintaining supercomplex integrity, SS-31 reduces mitochondrial reactive oxygen species at their source. This is mechanistically distinct from conventional antioxidants, which scavenge ROS after they're produced. SS-31 reduces ROS production itself—a upstream intervention rather than a downstream cleanup.

Key Research: The Clinical Trial Portfolio

The TAZPOWER Trial (Barth Syndrome)—The Approval Study

Design: Phase 2, randomized, double-blind, placebo-controlled crossover (Part 1: 28 weeks) followed by a 168-week open-label extension (Part 2).

Patients: 12 enrolled; 10 entered the open-label extension; 8 completed through week 168.

Dose: 40 mg subcutaneous daily.

Primary endpoints (Part 1): Change in 6-minute walk test (6MWT) distance and Barth Syndrome Symptom Assessment (BTHS-SA) Total Fatigue score. Part 1 did not meet its primary endpoints—the crossover design in 12 patients was underpowered.

Open-label extension results (Part 2): - 6MWT: cumulative improvement of 96.1 meters at week 168 (P = 0.003) and 122.7 meters at week 192 (P = 0.009) - Knee extensor muscle strength: significant improvement from baseline (the FDA's cited primary benefit) - BTHS-SA Fatigue scores: improved from baseline and maintained below baseline through week 192 - Cardiac function assessments showed positive trends

Safety: Injection site reactions (pruritus, erythema, induration) were the most common adverse events. All mild to moderate. No serious systemic adverse events. No treatment discontinuations due to adverse events.

Published: Genetics in Medicine, 2024 (PMID 38602181).

The editorial takeaway: This trial approved a drug on 12 patients in a crossover design that didn't hit its primary endpoints, followed by an uncontrolled extension that showed improvement over years. The FDA granted accelerated approval—meaning continued approval requires confirmatory trial data. This is exactly how accelerated approval is supposed to work for ultra-rare diseases: small populations where traditional trial design is impractical, with a regulatory mechanism that demands follow-up proof. The result is legitimate but conditional.

MMPOWER-3 (Primary Mitochondrial Myopathy)—The Biggest Trial

Design: Phase 3, randomized, double-blind, placebo-controlled. 218 patients (109 elamipretide, 109 placebo). 24 weeks. 40 mg subcutaneous daily.

Primary endpoints: 6MWT distance and Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) total fatigue. Did not meet primary endpoints.

But the subgroup story matters: Post-hoc analysis (PMID 39574155) found that patients with nuclear DNA (nDNA) pathogenic variants responded to elamipretide on the 6MWT. Patients with mitochondrial DNA (mtDNA) variants did not. This genotype-specific difference led to the NuPOWER trial, a Phase 3 study specifically enrolling the nDNA-PMM subgroup, which is fully enrolled as of 2025.

Published: Neurology, 2023 (PMID 37268435).

PROGRESS-HF (Heart Failure)—The Negative Trial

Design: Phase 2, randomized, double-blind, placebo-controlled. 71 patients with heart failure with reduced ejection fraction (LVEF ≤40%). 1:1:1 randomization to placebo, 4 mg elamipretide, or 40 mg elamipretide. 28 days. 20 European centers.

Primary endpoint: Change in left ventricular end-systolic volume (LVESV). Did not meet primary endpoint. No significant differences between groups in LVESV, ejection fraction, or end-diastolic volume.

Published: Circulation: Heart Failure, 2020 (PMID 32068002).

The editorial takeaway: 28 days may have been too short for a mitochondrial therapy to produce measurable cardiac remodeling. But we cannot assume that; we can only report that the trial was negative.

ReCLAIM-2 (Age-Related Macular Degeneration)—The Secondary Signal

Design: Phase 2b, randomized, double-masked, placebo-controlled. 176 patients (117 elamipretide, 59 placebo). Age ≥55, dry AMD with geographic atrophy. 48 weeks. 40 mg subcutaneous daily.

Primary endpoints: Mean change in low-luminance best-corrected visual acuity (LL BCVA) and mean change in geographic atrophy area. Did not meet primary endpoints.

Secondary/exploratory results that caught attention: - 43% reduction in mean progression of ellipsoid zone (EZ) attenuation/loss - 47% reduction in partial EZ degradation - 14.6% of elamipretide patients gained ≥10 letters in LL BCVA vs. 2.1% of placebo (P = 0.04)

Published: Ophthalmology Science, 2024 (PMID 39605874).

The editorial takeaway: The EZ attenuation findings have been designated as the primary endpoint for the Phase 3 ReNEW trial. This is a legitimate scientific pivot—but it's important to note that it required moving from a functional outcome (visual acuity) to an anatomical surrogate (retinal structure). Surrogate endpoints ≠ clinical outcomes.

Understanding Barth Syndrome

What the Disease Is

Barth syndrome is an X-linked genetic disease caused by mutations in the TAFAZZIN (TAZ) gene. The TAZ gene encodes an enzyme called tafazzin, which is responsible for remodeling cardiolipin—specifically, for replacing the acyl chains on immature cardiolipin with the correct linoleic acid chains that produce the mature, functional form called tetralinoleyl-cardiolipin.

When tafazzin is defective, cardiolipin remodeling fails. The consequences:

• Mature cardiolipin levels drop dramatically
• An abnormal intermediate—monolysocardiolipin (MLCL)—accumulates
• The inner mitochondrial membrane loses its proper structure
• Electron transport chain supercomplexes (Complexes I, III, IV, and V) can no longer organize correctly
• ATP production falls; reactive oxygen species rise
• Mitochondria in high-energy tissues—heart, skeletal muscle, immune cells—begin to fail

The clinical picture: cardiomyopathy (dilated or hypertrophic), skeletal muscle weakness, exercise intolerance, neutropenia (low white blood cells, leading to recurrent infections), and growth delay. The disease primarily affects males (X-linked recessive), typically manifests in childhood, and is progressive. Before FORZINITY, treatment was entirely supportive—cardiac medications, physical therapy, and in severe cases, heart transplant.

How Many People Are Affected

Barth syndrome affects approximately 150 individuals in the United States. Estimated incidence is 1–2 per 100,000 live births, though underdiagnosis is likely. The Barth Syndrome Foundation maintains a global registry and has been instrumental in coordinating research and advocacy.

Evidence: In Vitro, Animal, and Human

In Vitro

Cardiolipin binding and cytochrome c interaction characterized in cell-free systems. Mitochondrial membrane potential stabilization confirmed in isolated mitochondria. ROS reduction measured in cultured cell lines exposed to oxidative stress.

Animal Models

SS-31 has been tested in rodent models of ischemia-reperfusion injury (cardiac and renal), diabetic kidney disease, polycystic kidney disease, neuroinflammation (LPS-induced), and natural aging. Consistently positive results: improved mitochondrial function, reduced oxidative damage, preserved tissue architecture. The aged-mouse cardiac study (eLife, PMID approximately 32554501-adjacent) showed reversal of cardiac dysfunction with late-life SS-31 treatment—the most directly relevant preclinical finding for the longevity community.

Human Clinical Data

Over 700 patients have received elamipretide across major clinical trials. Safety data extends to 192 weeks (TAZPOWER). The compound is well-tolerated, with injection site reactions as the primary adverse event. Efficacy is established for Barth syndrome (accelerated approval) and under investigation for nDNA-associated mitochondrial myopathy, dry AMD with geographic atrophy, and additional indications.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

The clinical evidence for SS-31 is simultaneously strong and narrow. On the strong side: the mechanism of action is among the best-characterized of any compound on this site. Cardiolipin binding has been confirmed by biophysical studies, protein interaction mapping (PNAS 2020), and consistent biomarker changes across trials. The FDA approval is real—not a supplement claim, not an off-label inference, but a regulatory decision based on reviewed clinical data.

On the narrow side: that approval covers a condition affecting 150 Americans. The three trials that tested elamipretide in broader populations—conditions that affect millions—all missed their primary endpoints. The drug is now pursuing refined patient selections (nDNA-PMM subgroup in NuPOWER, EZ attenuation as endpoint in ReNEW) to find populations where the benefit is detectable. This is common in drug development but important to acknowledge: the mitochondrial mechanism may be too subtle for short trials in heterogeneous populations to capture.

For the longevity community, the gap is wider still. No clinical trial has tested SS-31 for age-related mitochondrial decline in otherwise healthy individuals. The preclinical data—aged mice showing cardiac improvement after SS-31 treatment—is genuinely interesting but remains preclinical. The leap from "stabilizes cardiolipin in a genetic disease" to "reverses mitochondrial aging in healthy adults" requires human evidence that does not yet exist.

Safety, Risks, and Limitations

Injection Site Reactions

The most common adverse events across all clinical trials are injection site reactions: pruritus (itching), erythema (redness), induration (hardening), bruising, and occasionally urticaria (hives). In some studies, 100% of elamipretide-treated patients experienced at least one injection site reaction. All were mild to moderate in severity, and none led to treatment discontinuation.

Management options include oral antihistamines and topical corticosteroids. A Phase 1 study found that topical mometasone applied prior to injection significantly reduced reaction severity. The reactions tend to improve with continued use.

Systemic Safety

No serious systemic adverse events have been reported in any clinical trial. No deaths attributed to elamipretide. No hepatic toxicity. No renal toxicity. No cardiac arrhythmias. The safety profile extends to 192 weeks of daily dosing in TAZPOWER, which is among the longest safety datasets for any peptide compound on this site.

Limitations

Accelerated approval carries conditions. The FDA requires confirmatory trial data to convert accelerated approval to full approval. If confirmatory data is negative, the approval can be withdrawn. This is not a hypothetical risk—the FDA has withdrawn accelerated approvals before.

Ultra-rare disease extrapolation. The 12-patient TAZPOWER trial does not generate the statistical power that larger trials do. The open-label extension was uncontrolled—all participants knew they were receiving the drug. Placebo effects, natural disease fluctuation, and regression to the mean are legitimate concerns in uncontrolled extension studies.

No evidence for anti-aging use. The leap from "treats Barth syndrome" to "treats aging" requires evidence that does not exist. Cardiolipin deterioration occurs in aging, and SS-31 stabilizes cardiolipin. But that syllogism is not a clinical trial.

Legal and Regulatory Status

FDA: Accelerated approval, September 19, 2025. FORZINITY (elamipretide HCl) injection. Indication: improvement of muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. Commercially available since December 4, 2025 through AnovoRx Specialty Pharmacy.

WADA: Not explicitly listed on the 2025–2026 Prohibited List. Athletes with diagnosed Barth syndrome could apply for a Therapeutic Use Exemption. Off-label use for performance enhancement has no regulatory guidance but could fall under general prohibited substance categories.

Compounding pharmacies: Prior to FDA approval, elamipretide was available as a research peptide through gray-market suppliers. Post-approval, the regulatory landscape is shifting. FDA enforcement against unregulated peptide sellers has intensified in 2025–2026, and the availability of gray-market SS-31 may decrease.

International: No EMA or other major regulatory approval outside the United States as of March 2026.

Research Protocols and Formulation Considerations

Formulation: FORZINITY is supplied as a sterile, preservative-free solution for subcutaneous injection. Pre-filled syringes contain 40 mg/mL elamipretide hydrochloride.

Storage: Refrigerated at 2–8 °C (36–46 °F). Protect from light. Do not freeze.

Administration: Single daily subcutaneous injection. Rotate injection sites (abdomen, thigh, upper arm). Patients are trained on self-administration by AnovoRx care coordinators.

Clinical trial formulations: Earlier studies used lyophilized powder requiring reconstitution with sterile water. The commercial formulation is a ready-to-use solution.

Dosing in Published Research

Every major clinical trial of elamipretide has used subcutaneous injection. The approved dose for Barth syndrome is 40 mg once daily—the same dose used across all Phase 3 programs. PROGRESS-HF tested both 4 mg and 40 mg arms, and earlier dose-escalation work in primary mitochondrial myopathy (PMID 28916603) explored multiple dose levels before the 40 mg dose was selected for subsequent trials. The table below summarizes published research dosing across all major programs.

Onset: Biomarker changes (cardiolipin ratios, mitochondrial function markers) have been measured within weeks. Functional improvement (6MWT, muscle strength) accumulated over months to years in TAZPOWER.

Duration of effect: Requires continuous daily dosing. No data on residual benefit after discontinuation in humans; animal models suggest mitochondrial benefits reverse when treatment stops.

Dosing in Self-Experimentation Communities

The following table summarizes community-reported dosing practices for SS-31 (Elamipretide). These are not clinical recommendations. No controlled trial data supports these protocols.

Combination Stacks

Research into SS-31 (Elamipretide) combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining SS-31 (Elamipretide) with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

SS-31 is the compound that shows you what real drug development looks like—and why most people find it disappointing. It is the first FDA-approved drug that directly targets the inner mitochondrial membrane. That is a genuine milestone. It is also a drug approved for 150 patients with one ultra-rare disease while three larger trials missed their marks. Both facts are true simultaneously, and the summary has to hold both.

The mechanism is the real deal. SS-31 binds cardiolipin in the inner mitochondrial membrane, stabilizes cristae structure, and improves electron transport chain efficiency. This is not a hand-waving mechanism or a cell-culture-only story. Multiple independent labs have confirmed the biochemistry. Szeto's group mapped the interaction with 17 mitochondrial proteins at the inner membrane. The mechanism is elegant, well-characterized, and replicated.

The FDA approval is real but extremely narrow. FORZINITY was approved in September 2025 for Barth syndrome—a genetic disorder affecting roughly 150 Americans—under accelerated approval based on a 12-patient TAZPOWER trial and its open-label extension. At week 192, survivors showed a 122.7-meter improvement in the 6-minute walk test. This is meaningful for Barth patients. It tells you almost nothing about whether SS-31 works for common diseases or aging.

Three larger trials all missed their primary endpoints. MMPOWER-3 (218 patients, mitochondrial myopathy), PROGRESS-HF (71 patients, heart failure), and ReCLAIM-2 (176 patients, macular degeneration)—none hit their primary endpoints. Each produced secondary signals that Stealth BioTherapeutics is pursuing in refined follow-up studies. But the honest read is that SS-31 has been tested in three common conditions and failed its primary goals in all three.

The anti-aging evidence does not exist. No controlled trial has tested elamipretide for age-related mitochondrial decline in healthy adults. The preclinical aging data is encouraging—aged mice showed rapid improvements in skeletal muscle mitochondrial energetics, and aged human cardiac tissue responded ex vivo. But mouse mitochondria and human tissue slices are not the same as injecting healthy older people. Every anti-aging claim about SS-31 is extrapolation from a Barth syndrome approval and preclinical models.

Safety is the one bright spot for broader use. Across all trials—including patients dosed for over three years in the TAZPOWER extension—the safety profile has been clean. Injection site reactions and headache are the most common adverse events. No organ toxicity, no immune reactions, no serious safety signals. This is the strongest argument that SS-31 could eventually find broader applications.

The pipeline is active. NuPOWER (mitochondrial myopathy, refined design) and ReNEW (AMD, longer duration) are ongoing. If either hits its primary endpoint, the story changes substantially. Until then, the data is what it is.

Verdict Recapitulation

SS-31 earns Tier 1 because it has FDA approval—a milestone that only two compounds on the entire Peptidings site have achieved. It earns "Strong Foundation" because the mechanism is well-characterized, independently replicated, and backed by a clean safety profile across multiple trials and years of follow-up.

But the tier and the verdict require context. The approval is for an ultra-rare condition based on a 12-patient trial. Three attempts to prove efficacy in common diseases have all missed their primary endpoints. No trial has tested the compound for aging. The strong foundation is real—the science beneath SS-31 is better than almost anything else in the peptide space—but the building on top of that foundation is still under construction.

For readers considering SS-31: if you want to understand what genuine mitochondrial medicine looks like, this compound is the best example that exists. If you want proof that it works for your specific health goal, the data probably is not there yet. Watch NuPOWER and ReNEW. The next two years will matter more than the last twenty.

For readers considering SS-31 (Elamipretide), the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source SS-31 (Elamipretide)

Further Reading and Resources

If you want to go deeper on SS-31 (Elamipretide), the evidence landscape for longevity & anti-aging peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Longevity & Anti-Aging Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: SS-31 (Elamipretide) — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Thompson et al., "Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER." Genetics in Medicine, 2024 PubMed
2. Karaa et al., "Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial." Neurology, 2023 PubMed
3. Karaa et al., "Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial." Orphanet Journal of Rare Diseases, 2024 PubMed
4. Butler et al., "Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial." Circulation: Heart Failure, 2020 PubMed
5. Liao et al., "ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration." Ophthalmology Science, 2024 PubMed
6. Szeto, "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." British Journal of Pharmacology, 2014 PubMed
7. Birk et al., "The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin." Journal of the American Society of Nephrology, 2013 PubMed
8. Chavez et al., "Mitochondrial protein interaction landscape of SS-31." Proceedings of the National Academy of Sciences, 2020 PubMed
9. Daubert et al., "Novel Mitochondria-Targeting Peptide in Heart Failure Treatment." Circulation: Heart Failure, 2018 PubMed
10. Karaa et al., "Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy." Neurology, 2018 PubMed
11. Szeto, "Cell-permeable, mitochondrial-targeted, peptide antioxidants." AAPS Journal, 2006 PubMed
12. Eirin et al., "Restoring mitochondrial superoxide levels with elamipretide (MTP-131) protects db/db mice against progression of diabetic kidney disease." Journal of Biological Chemistry, 2020 PubMed
13. Greggio et al., "Phase 1 Clinical Trial of Elamipretide in Dry AMD and Noncentral Geographic Atrophy: ReCLAIM NCGA Study." Ophthalmology Science, 2022 PubMed
14. Greggio et al., "Phase 1 Clinical Trial of Elamipretide in Intermediate AMD and High-Risk Drusen: ReCLAIM High-Risk Drusen Study." Ophthalmology Science, 2022 PubMed
15. Wu et al., "Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice." Journal of Neuroinflammation, 2019 PubMed
16. Siegel et al., "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice." Aging Cell, 2013 PubMed
17. Elamipretide Review, "Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential." International Journal of Molecular Sciences, 2025 PubMed
18. Szeto & Birk, "Serendipity and the discovery of novel compounds that restore mitochondrial plasticity." Clinical Pharmacology & Therapeutics, 2014 PubMed
19. Campbell et al., "Barth syndrome: cellular compensation of mitochondrial dysfunction." Biochimica et Biophysica Acta, 2013 PubMed
20. Campbell et al., "Tafazzin Mutation Affecting Cardiolipin Leads to Increased Mitochondrial Superoxide Anions." Cells, 2020 PubMed
21. Sabbah et al., "Elamipretide Improves Mitochondrial Function in the Failing Human Heart." JACC: Basic to Translational Science, 2019 PubMed
22. Allen et al., "The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator." GeroScience, 2023 PubMed

---